Treatment with phosphodiester CpG-ODN ameliorates atopic dermatitis by enhancing TGF-β signaling
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Synthetic oligodeoxynucleotides (ODNs) containing unmethylated CpG phosphorothioate (PS CpG-ODN) are known to decrease IgE synthesis in Th2 allergy responses. Nonetheless, the therapeutic role of PS CpG-ODN is limited due to cytotoxicity. Therefore, we developed a phosphodiester (PO) form of CpG-ODN (46O) with reduced toxicity but effective against allergies. In this study, we first compared the toxicity of 46O with CpG-ODNs containing a PS backbone (1826S). We also investigated the therapeutic efficacy and mechanism of 46O injected intravenously in a mouse model of ovalbumin (OVA)-induced atopic dermatitis (AD). To elucidate the mechanism of 46O underlying the inhibition of IgE production, IgE- and TGF-??-associated molecules were evaluated in CD40/IL-4- or LPS/IL-4-stimulated B cells. Our data showed that the treatment with 46O was associated with a lower hematological toxicity compared with 1826S. In addition, injection with 46O reduced erythema, epidermal thickness, and suppressed IgE and IL-4 synthesis in mice with OVA-induced AD. Additionally, 46O induced TGF-β production in LPS/IL-4-stimulated B cells via inhibition of Smad7, which suppressed IgE synthesis via interaction between Id2 and E2A. These findings suggest that enhanced TGF-β signaling is an effective treatment for IgE-mediated allergic conditions, and 46O may be safe and effective for treating allergic diseases such as AD and asthma.
Abstract
Synthetic oligodeoxynucleotides (ODNs) containing unmethylated CpG phosphorothioate (PS CpG-ODN) are known to decrease IgE synthesis in Th2 allergy responses. Nonetheless, the therapeutic role of PS CpG-ODN is limited due to cytotoxicity. Therefore, we developed a phosphodiester (PO) form of CpG-ODN (46O) with reduced toxicity but effective against allergies. In this study, we first compared the toxicity of 46O with CpG-ODNs containing a PS backbone (1826S). We also investigated the therapeutic efficacy and mechanism of 46O injected intravenously in a mouse model of ovalbumin (OVA)-induced atopic dermatitis (AD). To elucidate the mechanism of 46O underlying the inhibition of IgE production, IgE- and TGF-??-associated molecules were evaluated in CD40/IL-4- or LPS/IL-4-stimulated B cells. Our data showed that the treatment with 46O was associated with a lower hematological toxicity compared with 1826S. In addition, injection with 46O reduced erythema, epidermal thickness, and suppressed IgE and IL-4 synthesis in mice with OVA-induced AD. Additionally, 46O induced TGF-β production in LPS/IL-4-stimulated B cells via inhibition of Smad7, which suppressed IgE synthesis via interaction between Id2 and E2A. These findings suggest that enhanced TGF-β signaling is an effective treatment for IgE-mediated allergic conditions, and 46O may be safe and effective for treating allergic diseases such as AD and asthma.
참고문헌 (31)
- Eibensteiner P, "Immunoglobulin E antibodies of atopic individuals exhibit a broad usage of VH-gene families", Immunology, 101, pp.112~119 (2000)
- Calman Prussin DDM, "IgE, mast cells, basophils, and eosinophils", J Aller Clin Immunol, 111, pp.S486~S494 (2003)
- Gould HJ, "IgE in allergy and asthma today", Nat Rev Immunol, 8, pp.205~217 (2008)
- Li MO W, "Transforming growth factor-h regulation of immune responses", Annu Rev Immunol, 24, pp.99~146 (2006)
- Anthoni M, "Smad3 signal transducer regulates skin inflammation and specific IgE response in murine model of atopic dermatitis", J Invest Dermatol, 127, pp.1923~1929 (2007)
- Jin-ming Di JP, "Toll-like receptor 9 agonists promote IL-8 and TGF-b1production via activation of nuclear factor kB in PC-3cells", Cancer Genet Cytogenet, 192, pp.60~67 (2009)
- Bhagat L, "CpG penta-and hexadeoxyribonucleotides as potent immunomodulatory agents", Biochem Biophys Res Commun, 300, pp.853~861 (2003)
- Alexander H, "Phosphodiester CpG oligonucleotides as adjuvants : polyguanosine runs enhance cellular uptake and improve immunostimulative activity of phosphodiester CpG oligonucleotides in vitro and in vivo", Immunology, 106, pp.102~112 (2002)
- Verthelyi D, "CpG oligodeoxynucleotides as vaccine adjuvants in primates", J Immunol, 168, pp.1659~1663 (2002)
- Jiang W, "TLR9 stimulation drives naive B cells to proliferate and to attain enhanced antigen presenting function", Eur J Immunol, 37, pp.2205~2213 (2007)
- Serebrisky D, "CpG oligodeoxynucleotides can reverse Th2-associated allergic airway responses and alter the B7. 1", B7. 2 expression in a murine model of asthma, 2000, pp.165, 5906~5912
- Kusunoki T, "CpG inhibits IgE class switch recombination through suppression of NF kappa B activity, but not through Id2 or Bcl6", Biochem Biophys Res Commun, 328, pp.499~506 (2005)
- Tsujimura H, "Toll-like receptor 9 signaling activates NF-kappaB through IFN regulatory factor-8", IFN consensus sequence binding protein in dendritic cells, 2004, pp.172, 6820~6827
- 김두식, "Identification of Immunostimulatory Oligodeoxynucleotide from Escherichia coli Genomic DNA", BMB reports, 39(6), pp.788~793 (2006), 한국생화학분자생물학회
- 박성태, "Effect of Dendritic Cells Treated with CpG ODNon Atopic Dermatitis of Nc", Nga mice, 2007, pp.40(4), 486~493[DOI]
- Heikenwalder M, "Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration", Nat Med, 10, pp.187~192 (2004)
- Kootiratrakarn T, "Development of a novel Ag-specific immunotherapy using CpG oligodeoxynucleotides in a new, unique mouse cutaneous eosinophilic inflammation model", Eur J Immunol, 35, pp.3277~3286 (2005)
- Geha RS, "The regulation of immunoglobulin E class-switch recombination", Nat Rev Immunol, 3, pp.721~732 (2003)
- Yanagihara Y, "Molecular regulation of human IgE synthesis", Allergol Int, 48, pp.111~119 (1999)
- Sumiyoshi K, "Transforming growth factor-beta1 suppresses atopic dermatitis-like skin lesions in NC", Nga mice, 2002, pp.32, 309~314
- Suping Zhang TF, "Smad7 antagonizes TGF- signaling in the nucleus by interfering with functional Smad-DNA complex formation", Mol Cell Biol, 27, pp.4488~4499 (2007)
- Sugai M, "Essential role of Id2 in negative regulation of IgE class switching", Nat Immunol, 4, pp.25~30 (2003)
- Heikenwalder M, "Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration", Nat Med, 10, pp.187~192 (2004)
- Liu N, "CpG directly induced T-bet expression and inhibits IgG1 and IgE switching in B cells", Nat Immunol, 4, pp.687~693 (2003)
- Okamoto A, "Suppression of serum IgE response and systemic anaphylaxis in a food allergy model by orally administered high-dose TGF-beta", Int Immunol, 17, pp.705~712 (2005)
- Di J, "Toll-like receptor 9 agonists promote IL-8 and TGF-beta1 production via activation of nuclear factor kappaB in PC-3 cells", Cancer Genet Cytogenet, 192, pp.60~67 (2009)
- Quong MW, "E2A activity is induced during B-cell activation to promote immunoglobulin class switch recombination", EMBO J, 18, pp.6307~6318 (1999)
- Sugai M, "Essential role of Id2 in negative regulation of IgE class switching", Nat Immunol, 4, pp.25~30 (2003)
- Sugai M, "Role of Id proteins in B lymphocyte activation : new insights from knockout mouse studies", J Mol Med, 82, pp.592~599 (2004)
- Kim Y, "Improvement of atopic dermatitis in NC", Nga mice by topical application of CpG phosphodiester-ODN, 2007, pp.144, 315~324
- Nabe T, "Induction of a late asthmatic response associated with airway inflammation in mice", Eur J Pharmacol, 521, pp.144~155 (2005)